$POAI
Predictive Oncology Inc. Stock $poai

$poai Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000117184322003645 Filed on May 12, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$314.6K	$280.3K
YoY Change	12.22%	-4.96%
Cost Of Revenue	$109.4K	$97.76K
YoY Change	11.95%	5.51%
Gross Profit	$205.1K	$182.6K
YoY Change	12.36%	-9.75%
Gross Profit Margin	65.21%	65.13%
Selling, General & Admin	$2.728M	$3.385M
YoY Change	-19.42%	9.46%
% of Gross Profit	1329.98%	1854.42%
Research & Development	$68.22K	$93.63K
YoY Change	-27.14%	-27.61%
% of Gross Profit	33.26%	51.29%
Depreciation & Amortization	$323.6K	$322.0K
YoY Change	0.5%	55.86%
% of Gross Profit	157.76%	176.37%
Operating Expenses	$2.796M	$3.479M
YoY Change	-19.62%	7.97%
Operating Profit	-$3.414M	-$3.778M
YoY Change	-9.63%	9.84%
Interest Expense	$1.910K	$100.0K
YoY Change	-98.09%	100.0%
% of Operating Profit
Other Income/Expense, Net	$41.44K	-$210.0K
YoY Change	-119.73%	-75.0%
Pretax Income	-$3.371M	-$3.890M
YoY Change	-13.35%	-14.13%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$3.371M	-$3.889M
YoY Change	-13.32%	-14.14%
Net Earnings / Revenue	-1071.54%	-1387.26%
Basic Earnings Per Share	$0.05	$0.11
Diluted Earnings Per Share	-$51.20K	-$106.5K
COMMON SHARES
Basic Shares Outstanding	65.84M	36.51M
Diluted Shares Outstanding	65.84M	36.51M

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$25.12M	$27.30M
YoY Change	-8.0%	792.16%
Cash & Equivalents	$25.12M	$27.30M
Short-Term Investments
Other Short-Term Assets	$408.1K	$340.0K
YoY Change	20.03%	30.77%
Inventory	$455.7K	$292.8K
Prepaid Expenses
Receivables	$265.0K	$264.9K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$26.24M	$28.20M
YoY Change	-6.94%	653.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.336M	$3.975M
YoY Change	-41.25%	188.55%
Goodwill	$6.858M	$2.814M
YoY Change	143.72%	-82.07%
Intangibles	$3.893M	$3.316M
YoY Change	17.4%	-8.01%
Long-Term Investments
YoY Change
Other Assets	$75.62K	$116.3K
YoY Change	-34.96%
Total Long-Term Assets	$13.81M	$11.45M
YoY Change	20.63%	-46.25%
TOTAL ASSETS
Total Short-Term Assets	$26.24M	$28.20M
Total Long-Term Assets	$13.81M	$11.45M
Total Assets	$40.06M	$39.65M
YoY Change	1.02%	58.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.107M	$1.027M
YoY Change	7.77%	-67.17%
Accrued Expenses	$695.4K	$1.278M
YoY Change	-45.58%	-40.36%
Deferred Revenue	$182.6K	$154.2K
YoY Change	18.44%	249.42%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.681M	$3.261M
YoY Change	-17.78%	-73.65%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$63.10K	$163.1K
YoY Change	-61.31%	-18.45%
Total Long-Term Liabilities	$63.10K	$163.1K
YoY Change	-61.31%	-92.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.681M	$3.261M
Total Long-Term Liabilities	$63.10K	$163.1K
Total Liabilities	$2.878M	$4.109M
YoY Change	-29.95%	-72.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$131.4M	-$112.3M
YoY Change	17.05%	29.01%
Common Stock	$659.1K	$487.9K
YoY Change	35.07%	733.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$37.18M	$35.55M
YoY Change
Total Liabilities & Shareholders Equity	$40.06M	$39.65M
YoY Change	1.02%	58.31%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$3.371M	-$3.889M
YoY Change	-13.32%	-14.14%
Depreciation, Depletion And Amortization	$323.6K	$322.0K
YoY Change	0.5%	55.86%
Cash From Operating Activities	-$3.094M	-$3.322M
YoY Change	-6.88%	11.74%
INVESTING ACTIVITIES
Capital Expenditures	$45.40K	$391.7K
YoY Change	-88.41%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$80.24K	-$393.1K
YoY Change	-79.59%	1109.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$86.89K	$30.34M
YoY Change	-99.71%	413.23%
NET CHANGE
Cash From Operating Activities	-$3.094M	-$3.322M
Cash From Investing Activities	-$80.24K	-$393.1K
Cash From Financing Activities	$86.89K	$30.34M
Net Change In Cash	-$3.087M	$26.62M
YoY Change	-111.6%	816.26%
FREE CASH FLOW
Cash From Operating Activities	-$3.094M	-$3.322M
Capital Expenditures	$45.40K	$391.7K
Free Cash Flow	-$3.139M	-$3.714M
YoY Change	-15.47%	24.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	us-gaap	Liabilities Liabilities	2878274	USD
CY2021Q4	us-gaap	Liabilities Liabilities	3505587	USD
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	659065	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	656146	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	167931634	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	167649028	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-131410997	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-128040282	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	37180494	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	40265684	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40058768	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43771271	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	314568	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	280317	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	109443	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	97758	USD
CY2022Q1	us-gaap	Gross Profit GrossProfit	205125	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2511571	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3893438	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3962118	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	182559	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2423651	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	651921	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	40265684	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	814454	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3270777	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	75618	USD
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	891071	USD
CY2021Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	574812	USD
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	304467	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	114641	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3414064	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	167065	USD
CY2022Q1	poai	Stock Issued During Period Value Inducement To Equity Line StockIssuedDuringPeriodValueInducementToEquityLine	86885	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3777671	USD
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	66152747
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65906465
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65614597
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2022Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25115561	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28202615	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	264966	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	354196	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	455680	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	387684	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	408102	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	513778	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	26244309	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	29458273	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2335692	USD
CY2022Q1	us-gaap	Goodwill Goodwill	6857790	USD
CY2021Q4	us-gaap	Goodwill Goodwill	6857790	USD
CY2022Q1	us-gaap	Assets Assets	40058768	USD
CY2021Q4	us-gaap	Assets Assets	43771271	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1106811	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1021774	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	695416	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1262641	USD
CY2022Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	127572	USD
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	129480	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	182626	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	186951	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	568825	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	639662	USD
CY2022Q1	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	42430	USD
CY2021Q1	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	28259	USD
CY2022Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	989	USD
CY2021Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	234972	USD
CY2022Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	1908	USD
CY2021Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	95671	USD
CY2022Q1	poai	Stock Issued During Period Value Issued For Services And Other Adjustments StockIssuedDuringPeriodValueIssuedForServicesAndOtherAdjustments	162122	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3370715	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-72607	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3888713	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3093696	USD
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65835080
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36513300
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4325	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	101167	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2681250	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3240508	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	133926	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	239664	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	63098	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	25415	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	37683	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	36518	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3370715	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	37180494	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	2642681	USD
CY2021Q1	poai	Stock Issued During Period Value Accrued Interest StockIssuedDuringPeriodValueAccruedInterest	143573	USD
CY2021Q1	poai	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	4495270	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	514011	USD
CY2021Q1	poai	Stock Issued During Period Value Issued For Services And Other Adjustments StockIssuedDuringPeriodValueIssuedForServicesAndOtherAdjustments	-4048	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	565082	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3888713	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	35545087	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3370715	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3888713	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	323602	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	321980	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	36518	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	565082	USD
CY2022Q1	poai	Equity Instruments Issued For Management And Consulting EquityInstrumentsIssuedForManagementAndConsulting	162122	USD
CY2021Q1	poai	Equity Instruments Issued For Management And Consulting EquityInstrumentsIssuedForManagementAndConsulting	-4048	USD
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	244830	USD
CY2022Q1	poai	Gain Losses On Debt Revaluation GainLossesOnDebtRevaluation	1908	USD
CY2021Q1	poai	Gain Losses On Debt Revaluation GainLossesOnDebtRevaluation	95671	USD
CY2022Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1200	USD
CY2021Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-0	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-89230	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8050	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	67996	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3289	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-197123	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	55431	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	85037	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-345070	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-581267	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-82271	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3322091	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45399	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	391685	USD
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	34844	USD
CY2021Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1436	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-80243	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-393121	USD
CY2022Q1	poai	Proceeds From Issuance Or Sale Of Equity Net Of Stock Issuance Costs ProceedsFromIssuanceOrSaleOfEquityNetOfStockIssuanceCosts	0	USD
CY2021Q1	poai	Proceeds From Issuance Or Sale Of Equity Net Of Stock Issuance Costs ProceedsFromIssuanceOrSaleOfEquityNetOfStockIssuanceCosts	31077231	USD
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2021Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4495270	USD
CY2022Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	-0	USD
CY2021Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	4162744	USD
CY2022Q1	poai	Payments For Premium PaymentsForPremium	-0	USD
CY2021Q1	poai	Payments For Premium PaymentsForPremium	1073470	USD
CY2022Q1	poai	Proceeds From Issuance Of Stock Pursuant To Equity Line ProceedsFromIssuanceOfStockPursuantToEquityLine	86885	USD
CY2021Q1	poai	Proceeds From Issuance Of Stock Pursuant To Equity Line ProceedsFromIssuanceOfStockPursuantToEquityLine	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	86885	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30336287	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3087054	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	26621075	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	28202615	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	678332	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	25115561	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27299407	USD
CY2022Q1	poai	Stock Issued During Period Value Exchange Agreement Accrued Interest StockIssuedDuringPeriodValueExchangeAgreementAccruedInterest	0	USD
CY2021Q1	poai	Stock Issued During Period Value Exchange Agreement Accrued Interest StockIssuedDuringPeriodValueExchangeAgreementAccruedInterest	143573	USD
CY2022Q1	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2021Q1	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	514011	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25115561	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	0	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Accounting Policies and Estimates</b></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and during the reporting period. Actual results could materially differ from those estimates.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p>
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2022Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	264966	USD
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	354196	USD
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	182626	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	186951	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.865	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.848	pure
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	68219	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	93629	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Credit Risk</b></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any <em style="font: inherit;">one</em> financial institution. The Company has <em style="font: inherit;">zero</em> credit risk for cash amounts held in a single institution that are in excess of amounts issued by the Federal Deposit Insurance Corporation.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p>
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	187922	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	193287	USD
CY2022Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	242067	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	183410	USD
CY2022Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	25691	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	10987	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	455680	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	387684	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4598949	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4579909	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2263257	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2068338	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2335692	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2511571	USD
CY2022Q1	us-gaap	Depreciation Depreciation	220078	USD
CY2021Q1	us-gaap	Depreciation Depreciation	238932	USD
CY2022Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	4268158	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	374720	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3893438	USD
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	7958314	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1102648	USD
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	2893548	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3962118	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	103524	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	83048	USD
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36513300
CY2022Q1	us-gaap	Earnings Per Share Basic Distributed EarningsPerShareBasicDistributed	0.05
CY2021Q1	us-gaap	Earnings Per Share Basic Distributed EarningsPerShareBasicDistributed	0.11
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	36518	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	565082	USD
CY2020Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	294382	USD
CY2021Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	95671	USD
CY2021Q1	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	198711	USD
CY2021Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	129480	USD
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1908	USD
CY2022Q1	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	127572	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3370715	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3888713	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65835080
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36513300
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2021Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65835080
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	4	pure
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	314568	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	280317	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3370715	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3888713	USD
CY2022Q1	us-gaap	Assets Assets	40058768	USD
CY2021Q4	us-gaap	Assets Assets	43771271	USD

Files In Submission

Name	View Source	Status
0001171843-22-003645-index-headers.html	Edgar Link	pending
0001171843-22-003645-index.html	Edgar Link	pending
0001171843-22-003645.txt	Edgar Link	pending
0001171843-22-003645-xbrl.zip	Edgar Link	pending
ex_371735.htm	Edgar Link	pending
ex_371736.htm	Edgar Link	pending
ex_371737.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
poai-20220331.xsd	Edgar Link	pending
poai-20220331_cal.xml	Edgar Link	unprocessable
poai-20220331_def.xml	Edgar Link	unprocessable
poai-20220331_lab.xml	Edgar Link	unprocessable
poai-20220331_pre.xml	Edgar Link	unprocessable
poai20220331_10q.htm	Edgar Link	pending
poai20220331_10q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$POAI
Predictive Oncology Inc. Stock $poai

2022 Q1 Form 10-Q Financial Statement

#000117184322003645 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$POAI Predictive Oncology Inc. Stock $poai

2022 Q1 Form 10-Q Financial Statement

#000117184322003645 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$POAI
Predictive Oncology Inc. Stock $poai